|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0006560,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0205210,
umls-concept:C0229671,
umls-concept:C0439849,
umls-concept:C0441889,
umls-concept:C0444506,
umls-concept:C0666743,
umls-concept:C0871261,
umls-concept:C1550147,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-4-18
|
|
pubmed:abstractText |
To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0003-4967
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
704-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15485995-Adult,
pubmed-meshheading:15485995-Aged,
pubmed-meshheading:15485995-Antibodies, Monoclonal,
pubmed-meshheading:15485995-Antirheumatic Agents,
pubmed-meshheading:15485995-Arthritis, Rheumatoid,
pubmed-meshheading:15485995-Biological Markers,
pubmed-meshheading:15485995-C-Reactive Protein,
pubmed-meshheading:15485995-Dose-Response Relationship, Drug,
pubmed-meshheading:15485995-Drug Administration Schedule,
pubmed-meshheading:15485995-Drug Monitoring,
pubmed-meshheading:15485995-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15485995-Female,
pubmed-meshheading:15485995-Humans,
pubmed-meshheading:15485995-Male,
pubmed-meshheading:15485995-Middle Aged,
pubmed-meshheading:15485995-Prospective Studies,
pubmed-meshheading:15485995-Severity of Illness Index,
pubmed-meshheading:15485995-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
|
|
pubmed:affiliation |
Jan van Breemen Institute, Amsterdam, The Netherlands. g.wolbink@janvanbreemen.nl
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
